

**ABOUT THE TEST** FoundationOne®Heme is a comprehensive genomic profiling test designed to identify genomic alterations within hundreds of cancer-related genes in hematologic malignancies, sarcomas, and pediatric cancers.

**PATIENT**

**DISEASE** Acute myeloid leukemia (AML) (NOS)  
**NAME** Not Given  
**DATE OF BIRTH** Not Given  
**SEX** Female  
**MEDICAL RECORD #** Not Given

**PHYSICIAN**

**ORDERING PHYSICIAN** Not Given  
**MEDICAL FACILITY** Not Given  
**ADDITIONAL RECIPIENT** Not Given  
**MEDICAL FACILITY ID** Not Given  
**PATHOLOGIST** Not Given

**SPECIMEN**

**SPECIMEN SITE** Not Given  
**SPECIMEN ID** Not Given  
**SPECIMEN TYPE** Not Given  
**DATE OF COLLECTION** Not Given  
**SPECIMEN RECEIVED** Not Given

**Biomarker Findings**

**Microsatellite status - MS-Stable**  
**Tumor Mutational Burden - TMB-Low (2 Muts/Mb)**

**Genomic Findings**

*For a complete list of the genes assayed, please refer to the Appendix.*

**KIT D816V**  
**NRAS Q61H**  
**MYH11 CBFβ-MYH11 fusion**

**5 Therapies with Clinical Benefit**      **10 Clinical Trials**  
**2 Therapies with Lack of Response**

**BIOMARKER FINDINGS**

**Microsatellite status - MS-Stable**

**Tumor Mutational Burden - TMB-Low (2 Muts/Mb)**

**THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)**

No therapies or clinical trials. see Biomarker Findings section

**THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)**

No therapies or clinical trials. see Biomarker Findings section

**GENOMIC FINDINGS**

**KIT - D816V**

**7 Trials** see p. 16

**NRAS - Q61H**

**3 Trials** see p. 17

**THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)**

None

**THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)**

None

**⚠ 1. Patient may be resistant to indicated therapy**

**GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS**

*For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.*

**MYH11 - CBFβ-MYH11 fusion** ..... p. 18

**NOTE** Genomic alterations detected may be associated with activity of certain FDA-approved drugs; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type.